This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

Noteworthy studies presented at the 3rd European Lung Cancer Conference

April 11th, 2012

Abstracts submitted to the 3rd European Lung Cancer Conference (ELCC), co-organized by the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) will be released today (12:00 CEST) and available at http://www.esmo.org/events/lung-2012-elcc/program.html. Detailed results will be presented during the ELCC 2012, 18-21 April 2012 in Geneva, Switzerland.

Three studies have been indicated as noteworthy:

Abstract 164O

First perspective pre-planned and adequately sized study for evaluation of KRAS in non-small cell lung cancer patients who seem to have a higher risk of progression

Proffered Paper session, Thursday, April 19, 14:30-16:00, Room A&B

Abstract 166O

Favorable clinical benefit of potential new therapy with dacomitinib and improvements in common disease-related symptoms

Proffered Paper session, Thursday, April 19, 14:30-16:00, Room A&B

Abstract 77O

Validation of favorable prognostic role for survival of tumor lymphocytic infiltration in resectable non-small cell lung cancer

Proffered Paper session, Friday, April 20, 14:30-16:00, Room C

Provided by European Society for Medical Oncology

Citation: Noteworthy studies presented at the 3rd European Lung Cancer Conference (2012, April 11) retrieved 20 April 2024 from https://sciencex.com/wire-news/95594952/noteworthy-studies-presented-at-the-3rd-european-lung-cancer-con.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.